Serum soluble Fas-ligand levels and flow-mediated vasodilation in patients undergoing peritoneal dialysis
Abstract. Flow-mediated vasodilation (FMD) has been demonstrated to be a useful, non-invasive tool for the detection of endothelial dysfunction in atherosclerotic cardiovascular disease, the leading cause of mortality in end-stage kidney disease. The Fas/Fas ligand system of apoptosis resulting fro...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
State Institution «Institute of Nephrology NAMS of Ukraine"
2022-06-01
|
| Series: | Український Журнал Нефрології та Діалізу |
| Subjects: | |
| Online Access: | https://ukrjnd.com.ua/index.php/journal/article/view/611 |
| _version_ | 1797262198555279360 |
|---|---|
| author | Bülent Huddam Alper Azak Volkan Karakus Alper Alp Dilek Gibyeli Genek Meral Gülay Kadioglu Kocak Yelda Dere Dilek Ersil Soysal Murat Duranay |
| author_facet | Bülent Huddam Alper Azak Volkan Karakus Alper Alp Dilek Gibyeli Genek Meral Gülay Kadioglu Kocak Yelda Dere Dilek Ersil Soysal Murat Duranay |
| author_sort | Bülent Huddam |
| collection | DOAJ |
| description |
Abstract. Flow-mediated vasodilation (FMD) has been demonstrated to be a useful, non-invasive tool for the detection of endothelial dysfunction in atherosclerotic cardiovascular disease, the leading cause of mortality in end-stage kidney disease. The Fas/Fas ligand system of apoptosis resulting from activation of the caspase cascade- contributes to the pathophysiology of atherosclerosis. This ‘apoptotic’ system plays a central role in immune homeostasis. Vascular endothelial cells and inflammatory cells are the main resources of the Fas ligand. In this study, we aimed to investigate the role of soluble Fas ligand (sFasL) as a marker of FMD in peritoneal dialysis (PD) patients.
Methods. A total of 43 patients undergoing maintenance PD and 40 healthy donors were enrolled in this cross-sectional observational study. Demographics, anthropometric measurements and clinical examinations were obtained. Endothelial function was evaluated by FMD of the brachial artery with high-resolution ultrasonography. Serum sFasL concentrations were measured with an enzyme-linked immunosorbent assay kit.
Results. The enrolled partisipants were devited on 2 groups: PD patients who had been treated at least 12 weeks (group 1; mean age 41±14 years, M/F: 22/21) and gender matched 40 healthy controls (group 2; mean age 50±12 years, M/F: 19/20). The forearm FMD and serum sFasL levels were significantly lower in PD patients (3.95±2.01 vs 8.83 ± 6.17; p<0.001 and 54 ± 24 vs 73 ± 30; p=0.001). Forearm FMD was correlated with sFasL (r=0.289; p=0.008), age, BMI and uric acid (r= 0,32; p=0.003, respectively), hemoglobin (r= 0,293; p=0.007), calcium (r= 0,26; p=0.016), phosphate (r=- 0,250; p=0.023), magnesium (r= 0,255; p=0.020), 24 h SBP (r=- 0,257; p=0.019), creatinine and iPTH (r=- 0.50 and r=- 0,45; p<0.001, respectively). After adjustment for age, the stepwise multivariate analysis showed sFasL was independently associated to FMD (β: 0.180; p=0.03, CI: 0.078-0.314). vs 73 ± 30; p=0.001).
Conclusions. sFasL may be used as a simple screening marker for endothelial dysfunction in PD patients.
|
| first_indexed | 2024-04-24T23:53:18Z |
| format | Article |
| id | doaj.art-b50228b3681843e3b0649206a4f254ca |
| institution | Directory Open Access Journal |
| issn | 2304-0238 2616-7352 |
| language | English |
| last_indexed | 2024-04-24T23:53:18Z |
| publishDate | 2022-06-01 |
| publisher | State Institution «Institute of Nephrology NAMS of Ukraine" |
| record_format | Article |
| series | Український Журнал Нефрології та Діалізу |
| spelling | doaj.art-b50228b3681843e3b0649206a4f254ca2024-03-14T16:55:13ZengState Institution «Institute of Nephrology NAMS of Ukraine"Український Журнал Нефрології та Діалізу2304-02382616-73522022-06-012(74)10.31450/ukrjnd.2(74).2022.04Serum soluble Fas-ligand levels and flow-mediated vasodilation in patients undergoing peritoneal dialysisBülent Huddam0Alper Azak1Volkan Karakus2Alper Alp3Dilek Gibyeli Genek4Meral Gülay Kadioglu Kocak5Yelda Dere6Dilek Ersil Soysal7Murat Duranay8Mugla Sıtkı Koçman UniversityBalikesir State Hospital, Ministry of HealthAlanya Alaaddin Keykubat University, Alanya Training and Research HospitalMugla Sıtkı Koçman UniversityMugla Sıtkı Koçman UniversityOkmeydani Training and Research HospitalMugla Sıtkı Koçman UniversityIzmir University of EconomicsAnkara Education and Research Hospital Abstract. Flow-mediated vasodilation (FMD) has been demonstrated to be a useful, non-invasive tool for the detection of endothelial dysfunction in atherosclerotic cardiovascular disease, the leading cause of mortality in end-stage kidney disease. The Fas/Fas ligand system of apoptosis resulting from activation of the caspase cascade- contributes to the pathophysiology of atherosclerosis. This ‘apoptotic’ system plays a central role in immune homeostasis. Vascular endothelial cells and inflammatory cells are the main resources of the Fas ligand. In this study, we aimed to investigate the role of soluble Fas ligand (sFasL) as a marker of FMD in peritoneal dialysis (PD) patients. Methods. A total of 43 patients undergoing maintenance PD and 40 healthy donors were enrolled in this cross-sectional observational study. Demographics, anthropometric measurements and clinical examinations were obtained. Endothelial function was evaluated by FMD of the brachial artery with high-resolution ultrasonography. Serum sFasL concentrations were measured with an enzyme-linked immunosorbent assay kit. Results. The enrolled partisipants were devited on 2 groups: PD patients who had been treated at least 12 weeks (group 1; mean age 41±14 years, M/F: 22/21) and gender matched 40 healthy controls (group 2; mean age 50±12 years, M/F: 19/20). The forearm FMD and serum sFasL levels were significantly lower in PD patients (3.95±2.01 vs 8.83 ± 6.17; p<0.001 and 54 ± 24 vs 73 ± 30; p=0.001). Forearm FMD was correlated with sFasL (r=0.289; p=0.008), age, BMI and uric acid (r= 0,32; p=0.003, respectively), hemoglobin (r= 0,293; p=0.007), calcium (r= 0,26; p=0.016), phosphate (r=- 0,250; p=0.023), magnesium (r= 0,255; p=0.020), 24 h SBP (r=- 0,257; p=0.019), creatinine and iPTH (r=- 0.50 and r=- 0,45; p<0.001, respectively). After adjustment for age, the stepwise multivariate analysis showed sFasL was independently associated to FMD (β: 0.180; p=0.03, CI: 0.078-0.314). vs 73 ± 30; p=0.001). Conclusions. sFasL may be used as a simple screening marker for endothelial dysfunction in PD patients. https://ukrjnd.com.ua/index.php/journal/article/view/611peritoneal dialysis, flow-mediated vasodilation, soluble Fas-ligand, endothelial dysfunction. |
| spellingShingle | Bülent Huddam Alper Azak Volkan Karakus Alper Alp Dilek Gibyeli Genek Meral Gülay Kadioglu Kocak Yelda Dere Dilek Ersil Soysal Murat Duranay Serum soluble Fas-ligand levels and flow-mediated vasodilation in patients undergoing peritoneal dialysis Український Журнал Нефрології та Діалізу peritoneal dialysis, flow-mediated vasodilation, soluble Fas-ligand, endothelial dysfunction. |
| title | Serum soluble Fas-ligand levels and flow-mediated vasodilation in patients undergoing peritoneal dialysis |
| title_full | Serum soluble Fas-ligand levels and flow-mediated vasodilation in patients undergoing peritoneal dialysis |
| title_fullStr | Serum soluble Fas-ligand levels and flow-mediated vasodilation in patients undergoing peritoneal dialysis |
| title_full_unstemmed | Serum soluble Fas-ligand levels and flow-mediated vasodilation in patients undergoing peritoneal dialysis |
| title_short | Serum soluble Fas-ligand levels and flow-mediated vasodilation in patients undergoing peritoneal dialysis |
| title_sort | serum soluble fas ligand levels and flow mediated vasodilation in patients undergoing peritoneal dialysis |
| topic | peritoneal dialysis, flow-mediated vasodilation, soluble Fas-ligand, endothelial dysfunction. |
| url | https://ukrjnd.com.ua/index.php/journal/article/view/611 |
| work_keys_str_mv | AT bulenthuddam serumsolublefasligandlevelsandflowmediatedvasodilationinpatientsundergoingperitonealdialysis AT alperazak serumsolublefasligandlevelsandflowmediatedvasodilationinpatientsundergoingperitonealdialysis AT volkankarakus serumsolublefasligandlevelsandflowmediatedvasodilationinpatientsundergoingperitonealdialysis AT alperalp serumsolublefasligandlevelsandflowmediatedvasodilationinpatientsundergoingperitonealdialysis AT dilekgibyeligenek serumsolublefasligandlevelsandflowmediatedvasodilationinpatientsundergoingperitonealdialysis AT meralgulaykadioglukocak serumsolublefasligandlevelsandflowmediatedvasodilationinpatientsundergoingperitonealdialysis AT yeldadere serumsolublefasligandlevelsandflowmediatedvasodilationinpatientsundergoingperitonealdialysis AT dilekersilsoysal serumsolublefasligandlevelsandflowmediatedvasodilationinpatientsundergoingperitonealdialysis AT muratduranay serumsolublefasligandlevelsandflowmediatedvasodilationinpatientsundergoingperitonealdialysis |